Related Experiment Video
Updated: Aug 19, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Low frequency of mtDNA point mutations in patients with PEO associated with POLG1 mutations
Gittan Kollberg1, Monica Jansson, Asa Pérez-Bercoff
1Department of Pathology, Sahlgrenska University Hospital, Göteborg, Sweden.
Abstract:
Mitochondrial myopathy in progressive external ophthalmoplegia (PEO) has been associated with POLG1 mutations. POLG1 encodes the catalytic alpha subunit of polymerase gamma and is the only polymerase known to be involved in mtDNA replication. It has two functionally different domains, one polymerase domain and one exonuclease domain with proofreading activity. In this study we have investigated whether mtDNA point mutations are involved, directly or indirectly, in the pathogenesis of PEO. Muscle biopsy specimens from patients with POLG1 mutations, affecting either the exonuclease or the polymerase domain, were investigated. Single cytochrome c oxidase (COX)-deficient muscle fibers were dissected and screened for clonally expanded mtDNA point mutations using a sensitive denaturing gradient gel electrophoresis analysis, in which three different regions of mtDNA, including five different tRNA genes, were investigated. To screen for randomly distributed mtDNA point mutations in muscle, two regions of mtDNA including deletion breakpoints were investigated by high-fidelity PCR, followed by cloning and sequencing. Long-range PCR revealed multiple mtDNA deletions in all the patients but not the controls. No point mutations were identified in single COX-deficient muscle fibers. Cloning and sequencing of muscle homogenate identified randomly distributed point mutations at very low frequency in patients and controls (<1:50 000). We conclude that mtDNA point mutations do not appear to be directly or indirectly involved in the pathogenesis of mitochondrial disease in patients with different POLG1 mutations.
Insights
Mitochondrial myopathy, progressive external ophthalmoplegia (PEO), and POLG1 mutations are linked. This study found no evidence that mtDNA point mutations cause PEO in patients with POLG1 mutations, despite multiple mtDNA deletions.
Area of Science:
- Genetics
- Molecular Biology
- Neurology
Background:
- Progressive external ophthalmoplegia (PEO) is a mitochondrial myopathy often linked to mutations in POLG1, the gene encoding the catalytic alpha subunit of polymerase gamma.
- POLG1 is crucial for mitochondrial DNA (mtDNA) replication and possesses both polymerase and exonuclease domains.
Purpose of the Study:
- To investigate the direct or indirect role of mitochondrial DNA (mtDNA) point mutations in the pathogenesis of progressive external ophthalmoplegia (PEO).
- To analyze muscle biopsy specimens from patients with POLG1 mutations affecting either the exonuclease or polymerase domain.
Main Methods:
- Dissection and screening of single cytochrome c oxidase (COX)-deficient muscle fibers for clonally expanded mtDNA point mutations using denaturing gradient gel electrophoresis.
- Screening for randomly distributed mtDNA point mutations in muscle homogenates via high-fidelity PCR, cloning, and sequencing.
- Detection of multiple mtDNA deletions using long-range PCR.
Main Results:
- No point mutations were identified in single COX-deficient muscle fibers.
- Randomly distributed point mutations were found at very low frequencies in both patients and controls.
- Multiple mtDNA deletions were consistently detected in all patients but not in controls.
Conclusions:
- Mitochondrial DNA point mutations do not appear to be directly or indirectly involved in the pathogenesis of mitochondrial disease in patients with POLG1 mutations.
- The presence of multiple mtDNA deletions in patients suggests they are a consequence rather than a cause of the disease in this context.
More Related Videos
10:41Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
08:56Modeling Mitochondrial Disease Using Brain Organoids: A Focus on Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes
Published on: October 10, 2025
Related Concept Videos
Mutations
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Point and Frameshift Mutations